| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 350.45% | Cantor Fitzgerald | $2.5 → $2 | Maintains | Overweight |
| 08/23/2023 | 1026.13% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/08/2023 | 800.9% | Chardan Capital | $3.5 → $4 | Maintains | Buy |
| 04/17/2023 | 1026.13% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 04/14/2023 | 688.29% | Chardan Capital | → $3.5 | Maintains | Buy |
| 03/01/2023 | 688.29% | Chardan Capital | → $3.5 | Upgrades | Neutral → Buy |
| 03/01/2023 | 575.68% | Mizuho | $5 → $3 | Maintains | Buy |
| 03/01/2023 | 1026.13% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 08/23/2022 | 1026.13% | Mizuho | → $5 | Initiates Coverage On | → Buy |
| 08/15/2022 | 1251.35% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 06/15/2022 | 1701.8% | Roth Capital | → $8 | Reinstates | → Buy |
| 06/02/2022 | 913.51% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
| 05/12/2022 | 1476.58% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 02/28/2022 | 1701.8% | HC Wainwright & Co. | $10 → $8 | Maintains | Buy |
| 06/11/2021 | 1251.35% | Roth Capital | $10 → $6 | Downgrades | Buy → Neutral |
| 06/11/2021 | 2152.25% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/07/2021 | 2377.48% | Cantor Fitzgerald | $15 → $11 | Downgrades | Overweight → Neutral |
| 03/03/2021 | 3278.38% | Cantor Fitzgerald | $4 → $15 | Maintains | Overweight |
| 02/09/2021 | 2827.93% | Chardan Capital | $0.7 → $13 | Downgrades | Buy → Neutral |
| 02/04/2021 | 913.51% | HC Wainwright & Co. | → $4.5 | Upgrades | Neutral → Buy |
| 11/17/2020 | 125.23% | Roth Capital | → $1 | Initiates Coverage On | → Buy |
| 10/09/2020 | 125.23% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
| 06/03/2020 | 57.66% | Chardan Capital | $2 → $0.7 | Maintains | Buy |
| 06/01/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 12/20/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 11/27/2019 | 350.45% | Chardan Capital | → $2 | Initiates Coverage On | → Buy |
What is the target price for Ocugen (OCGN)?
The latest price target for Ocugen (NASDAQ: OCGN) was reported by Cantor Fitzgerald on August 31, 2023. The analyst firm set a price target for $2.00 expecting OCGN to rise to within 12 months (a possible 350.45% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ocugen (OCGN)?
The latest analyst rating for Ocugen (NASDAQ: OCGN) was provided by Cantor Fitzgerald, and Ocugen maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Ocugen (OCGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocugen was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
Is the Analyst Rating Ocugen (OCGN) correct?
While ratings are subjective and will change, the latest Ocugen (OCGN) rating was a maintained with a price target of $2.50 to $2.00. The current price Ocugen (OCGN) is trading at is $0.44, which is out of the analyst's predicted range.